Incyclix Bio, LLC competitors & alternatives

Similar pharmaceuticals company

Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.

Dignify Therapeutics, LLCPharmaceuticalsUnited States

67% match

Similar pharmaceuticals company

Dignify Therapeutics is a biotechnology company located in Research Triangle Park, North Carolina. The company focuses on developing pharmaceutical solutions to bolster bowel and bladder control for patients.

Similar pharmaceuticals company

Danqing Pharmaceuticals is a pharmaceutical company headquartered in Beijing with a U.S. subsidiary in Boston. The company focuses on first-in-class drug discovery and development in oncology, targeting therapeutic areas such as breast, gynecological, and gastrointestinal cancers.

Similar pharmaceuticals company

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Similar pharmaceuticals company

PMV Pharmaceuticals is a company developing first-in-class p53 regulators for the treatment of cancer by harnessing the power of the p53 protein.

Similar pharmaceuticals company

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

Similar pharmaceuticals company

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

Similar pharmaceuticals company

Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.

Deciphera PharmaceuticalsPharmaceuticalsUnited States

64% matchPrivateAI 4/100 ▲Green 0/100

Similar pharmaceuticals company

Deciphera Pharmaceuticals, LLC is a commercial-stage biopharmaceutical company dedicated to delivering transformational medicines, such as QINLOCK, to patients for the treatment of cancer and rare diseases.

Zentalis Pharmaceuticals, Inc.ZNTL · PharmaceuticalsSan Diego, United States

64% matchPublic

Similar pharmaceuticals company

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Shorla PharmaPharmaceuticalsIreland

63% match

Similar pharmaceuticals company

Shorla Pharma (operating as Shorla Oncology) develops and commercializes innovative oncology drugs, focusing on indications where existing treatments are limited, in shortage, or inadequate. The company provides specialized cancer treatments and accessible pharmaceutical options for patients.

SciTech Development L.L.C.Biotechnology & PharmaceuticalsUnited States

63% matchPrivate

Biotechnology & Pharmaceuticals

SciTech Development L.L.C. is a clinical-stage specialty oncology pharmaceutical company that develops safer drug delivery platforms and targeted cancer therapeutics. The company's lead candidate, ST-001 nanoFenretinide, is a patented treatment designed for lymphoma and other cancer indications.